Introduction/Overview
Natural products, as important resources for drug development, have always been a treasure trove for the discovery of anti-cancer drugs due to their structural diversity and wide range of biological activities. Cussosaponin C is a triterpenoid saponin natural product isolated from the Ranunculaceae plant Pulsatilla koreana Nakai. In recent years, it has attracted widespread attention due to its potential therapeutic value in breast cancer and other malignant tumors. Breast cancer is one of the most common malignant tumors in women. its treatment is facing the challenge of high drug resistance and recurrence rate. Ku Su Hua saponin C exhibits excellent anti-tumor activity by regulating multiple signaling pathways and molecular targets, particularly in regulating cellular energy metabolism, apoptosis, transcription factor activity, and drug efflux pumps.
In this paper, the chemical structure, physicochemical properties, plant sources and extraction methods of saponin C from Sophora frutescens were reviewed, its pharmacological activity and mechanism of action were systematically summarized, its molecular target interactions related to breast cancer were emphatically analyzed, its pharmaceutical properties and pharmacokinetic characteristics were evaluated, and its clinical application prospects and future research directions were explored, in order to provide scientific basis and theoretical support for the development and utilization of this natural product.
Chemical structure and physicochemical properties
Ku Su Hua saponin C is a relatively large triterpenoid saponin with a molecular weight of 1277.4000. It has a complex chemical structure and contains multiple glycosidic groups and triterpenoid parent nuclei. Its LogP value is about -0.5, indicating strong hydrophilicity, and its extremely high polar surface area (TPSA) reaches 409.04 Å ², indicating the presence of a large number of polar groups on the molecular surface, especially hydroxyl and glycosidic bonds. The number of hydrogen bond acceptors is as high as 25, further supporting its highly polar characteristics. These physical and chemical properties suggest that the membrane permeability of Kusunoside C in vivo is poor, especially difficult to cross the blood-brain barrier (BBB), which limits its potential application in central nervous system diseases.
Structurally, Ku Su Hua saponin C belongs to the saponin class of natural products. The typical triterpenoid saponin structure consists of hydrophobic triterpenoid parent nuclei and hydrophilic sugar chains. The type, connection method, and position of the sugar chains have a significant impact on their biological activity and pharmacokinetic properties. The degree of glycosylation of Kusunoside C is relatively high, which not only affects its solubility and stability, but also may affect its binding affinity with targets and intracellular transport.
Plant sources and extraction methods
Ku Su Hua saponin C is mainly derived from the Ranunculaceae plant Pulsatilla koreana Nakai, commonly known as Ku Su Hua. It is a traditional Chinese medicinal herb in East Asia and has the effects of clearing heat, detoxifying, reducing swelling, and relieving pain. Pulsatilla koreana is widely distributed in South Korea, Northeast China, and Japan, and its roots and whole plant are commonly used in traditional Chinese medicine.
The process of extracting saponins C from Sophora japonica usually includes the following steps: first, ethanol or methanol is used to reflux extract the dried plant powder to obtain a crude saponin mixture; Subsequently, separation and purification were carried out through liquid-liquid distribution, silica gel column chromatography, and high-performance liquid chromatography (HPLC). Due to the large molecular weight and strong polarity of Kusunoside C, it is necessary to optimize the solvent system and column chromatography conditions during the purification process to improve yield and purity. In recent years, the application of ultrasound assisted extraction and efficient separation technology has significantly improved the extraction efficiency and quality control level of saponins C from Sophora japonica.
Pharmacological activity research
Sophora frutescens saponin C has shown significant anti-tumor activity in a variety of cells and animal models, especially in the field of breast cancer. In vitro experiments showed that saponin C of Sophora frutescens could inhibit the proliferation of breast cancer cells, induce apoptosis, and inhibit the migration and invasion of tumor cells. Its anti-cancer effect is closely related to the regulation of multiple signaling pathways.
In addition, Ku Su Hua saponin C has inhibitory effects on tumor resistance related proteins such as ABCB1 and ABCG2, which can reverse multidrug resistance (MDR) in tumor cells and improve the sensitivity of chemotherapy drugs. In animal experiments, bitter Su flower saponin C showed good anti-tumor effects, significantly prolonged the survival of tumor model mice, and had low toxic side effects.
In addition to its anticancer activity, bitter Su flower saponin C also has certain anti-inflammatory, antioxidant, and immune regulatory effects. These auxiliary effects may synergistically enhance its anti-tumor effect, providing support for its multi-target and multi mechanism pharmacological activity.
Mechanism of action and molecular targets
Sophora frutescens saponin C plays an anti breast cancer role by regulating a variety of key molecular targets, mainly involving the following aspects:
-
AMPK (PRKAA1) activation
AMPK, as a core regulatory factor of cellular energy metabolism, regulates cellular metabolic homeostasis and autophagy. Sophora frutescens saponin C can activate AMPK signaling pathway, inhibit metabolic reprogramming of breast cancer cells, induce energy depletion, and promote cell apoptosis.
-
Regulation of anti apoptotic protein BCL2
BCL2 family proteins are key regulatory factors of cell apoptosis. Ku Su Hua saponin C downregulates BCL2 expression, disrupts the intracellular anti apoptotic barrier, and promotes mitochondrial mediated apoptosis.
-
STAT3 signaling pathway inhibition
STAT3, as a transcription factor, plays an important role in tumor cell proliferation and immune escape. Ku Su Hua saponin C inhibits the phosphorylation and nuclear translocation of STAT3, blocks the expression of its target genes, and inhibits the growth and metastasis of tumor cells.
-
Regulation of estrogen receptor beta (ESR2)
ESR2 can inhibit the growth of breast cancer. Sophora frutescens saponin C may affect the hormone dependent growth of breast cancer cells by regulating the expression or activity of ESR2.
-
Inhibition of drug efflux pumps ABCB1 and ABCG2
These two ATP binding cassette transporters are the main causes of multidrug resistance in tumors. Ku Su Hua saponin C inhibits its function, enhances the accumulation of chemotherapy drugs in tumor cells, and reverses drug resistance.
-
Protein kinase C alpha (PRKCA) and microtubule associated protein Tau (MAPT)
Ku Su Hua saponin C regulates PRKCA activity, affects cell signaling and proliferation, and inhibits tumor cell migration and invasion by affecting MAPT stable microtubule structure.
-
Activation of Nuclear Factor E2 Associated Factor 2 (NFE2L2)
NFE2L2 regulates cellular antioxidant response, and bitter Su flower saponin C reduces oxidative stress, protects normal cells, and enhances anti-tumor effect by regulating NFE2L2 signaling.
-
Topoisomerase I (TOP1) inhibition
TOP1 plays a crucial role in DNA replication and transcription, and bitter Su flower saponin C inhibits TOP1 activity, blocks tumor cell DNA synthesis, and induces cell cycle arrest.
To sum up, Sophora frutescens saponin C comprehensively regulates the metabolism, apoptosis, proliferation and drug resistance mechanism of breast cancer cells through multiple targets and multiple pathways, showing a unique anti-tumor potential.
Evaluation of drug properties and pharmacokinetics
The pharmacological evaluation of Ku Su Hua saponin C shows that it has certain challenges. Firstly, the high molecular weight (1277.4 Da) far exceeds the recommended upper limit of 500 Da by Lipinski's rule, indicating that its oral bioavailability may be low. Secondly, the high polarity (TPSA 409.04 Å ²) and a large number of hydrogen bond receptors limit its cell membrane permeability, especially making it difficult to cross the blood-brain barrier, which limits its application in central nervous system diseases.
At present, there is no clear safety data regarding the hepatotoxicity, cardiotoxicity (including hERG channel inhibition), and genotoxicity (Ames test) of Sophora flavescens saponins C, and further systematic evaluation is needed. In terms of pharmacokinetics, the absorption, distribution, metabolism, and excretion (ADME) characteristics of Kusunoside C have not been fully reported, and it is expected that its oral absorption will be limited. Therefore, it may be necessary to improve the dosage form or administration route (such as intravenous injection) to increase in vivo exposure.
In addition, the high polarity and high molecular weight of bitter Su flower saponin C may lead to its rapid action by metabolic enzymes in the body or excretion through the kidneys, limiting its clinical application due to its short half-life. In the future, strategies such as structural modification and nanocarrier encapsulation can be used to improve its pharmacokinetic properties, enhance bioavailability and targeting.
Clinical application prospects and prospects
As a multi target anti breast cancer natural product, Sophora frutescens saponin C has strong anti-tumor activity and potential ability to reverse multidrug resistance, showing a good prospect for clinical development. Its multiple action mechanisms in regulating energy metabolism, anti apoptosis, signal transduction and drug efflux provide a new idea for the comprehensive treatment of breast cancer.
However, the clinical translation of Ku Su Hua saponin C still faces many challenges, including poor pharmacokinetic properties, lack of safety data, and difficulties in formulation development. Future research should focus on the following directions:
-
Pharmacokinetic and toxicological studies of the system
Clarify the in vivo metabolic pathway, half-life, and potential toxicity of Ku Su Hua saponin C, providing a basis for clinical dose design.
-
Structural optimization and drug design
Reducing molecular polarity through chemical modification, improving membrane permeability, and enhancing oral bioavailability.
-
Development of a new drug delivery system
Using nanotechnology, liposomes, or polymer carriers to achieve targeted delivery, enhance drug accumulation at the tumor site, and reduce systemic toxic side effects.
-
Exploration of Combination Medication Strategy
Combining with existing chemotherapy drugs or targeted drugs to achieve synergistic effects and overcome drug resistance.
-
Preclinical and clinical trial advancement
Conduct long-term toxicological evaluation of animal models and preliminary clinical safety and efficacy studies to promote the clinical application of Kusunoside C.
In a word, as a potential candidate molecule for natural product drug development, Sophora frutescens saponin C is expected to become an important innovative drug in the field of breast cancer treatment in combination with modern pharmaceutical chemistry, pharmacology and pharmaceutical multidisciplinary research.
Conclusion
As an important active ingredient in Pulsatilla koreana Nakai, Sophora frutescens saponin C, with its unique triterpene saponin structure and multi-target anti-tumor mechanism, has shown broad application prospects in the research of breast cancer treatment. It exerts a comprehensive effect of anti proliferation, pro apoptosis, and reversal of drug resistance by regulating key molecular targets such as AMPK, BCL2, STAT3, ESR2, ABCB1, and ABCG2, demonstrating the enormous value of natural products in the development of anticancer drugs.
Despite limitations in terms of drug efficacy and pharmacokinetics, with technological advancements and interdisciplinary integration, the clinical translational potential of Kusunoside C continues to increase. In the future, in-depth mechanism research, safety evaluation and drug design optimization will lay a solid foundation for it to become a new generation of breast cancer drugs. The multi-target characteristics and low toxicity advantages of natural products make it possible for Kusunoside C to play an important role in precision medicine and personalized treatment, promoting the clinical application of natural product pharmacology.
